Keywords: truvada/sustiva, cuts, viral, load, vs, combivir/sustiva, usa-based
Truvada/Sustiva cuts viral load vs Combivir/Sustiva
Article | 06 August 2007
USA-based Gilead Sciences presented strong 144-week data from an ongoing clinical trial comparing a once-daily regimen of its product Truvada ( ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
